Anixa Biosciences, Inc. (ANIX)
Chart Events
Performance Outlook
| Previous Close | 4.4300 |
| Open | 4.4300 |
| Bid | 4.2200 x 2900 |
| Ask | 4.4000 x 900 |
| Day's Range | 4.1800 - 4.4300 |
| 52 Week Range | 1.3300 - 5.4000 |
| Volume | 465,112 |
| Avg. Volume | 637,998 |
| Market Cap | 109.783M |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4510 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.75 |
- PR Newswire
Anixa Biosciences to Present at the B. Riley Oncology Investor Conference
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at B. Riley's Inaugural Oncology Investor Conference to be held January 20-21, 2021.
- PR Newswire
Anixa Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021.
- PR Newswire
Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast Cancer Vaccine
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its breast cancer vaccine.
